Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Drugs Process-for-the-preparation-of-a-new-type-active-substance-selectively-inhibiting-food-intake

 Resolution of D,L-dehydroproline
I claim: 1. A method for the preparation of L-3,4-dehydroproline comprising in combination the ...


 Quaternary salts as hypoglycemic agents
OF THE INVENTION The hypoglycemic agents of the present invention are synthesized by the reaction ...


 7-[.alpha.-(2-Aminomethyl-1-cyclohexenyl)-acetamido]-3-heterocyclic thiomethyl-3-cephem-4-carboxylic acids
We claim: 1. An acid having the formula ##SPC42## wherein R is ##SPC43## ##SPC44## or ##EQU1## or a ...


 Pasteurized therapeutically active protein compositions
What is claimed is: 1. A method of pasteurizing a composition comprising a thermally sensitive, ...


 Method of preparing a high-purity, virus safe, biologically active transferrin preparation
We claim: 1. A method of preparing a high-purity, virus-safe biologically active, transferrin ...


 Hydrolyzable resin composition and an antifouling coating composition containing the same
What is claimed is: 1. A method of preventing marine fouling which comprises applying to a surface ...


 Treatment for herpes virus
OF THE INVENTION According to the invention, I provide a composition for and method of use of such ...


 Microbicidal meta oxy- and thio-substituted phenylanilines
What is claimed is: 1. A compound of the formula I, including salts and metal complexes thereof ##ST...


 Synergistic microbiocidal composition containing a mixture of a bicyclic polyoxymethyleneoxazolidine and an acroloin/formaldehyde polycondensation product
We claim: 1. A microbiocidal composition comprising a synergistic mixture the first component of ...


 Substituted acyl derivatives of amino acids
OF THE INVENTION The invention in its broad aspects includes substituted acyl derivatives of amino ...


 Process for the preparation of a new-type active substance selectively inhibiting food intake

Details
Inventors: Knoll, Jozsef; Nagy, Janos; Kalasz, Huba; Knoll, Berta;
Assignee: Richter Gedeon Vegyeszeti Gyar Rt. (Budapest, HU)
Primary Examiner:
Assistant Examiner:
Attorney, Agent or Firm:

The invention involves isolating a food intake suppressant by subjecting blood serum to ultrafiltration transmitting up to a molecular weight of 30,000 daltons, partially evaporating the filtrate, removing the insoluble part from the concentrate obtained, adding trichloroacetic acid up to a concentration of 5 to 25 weight/volume percent to the liquid phase at a temperature of 0.degree. to 10.degree. C., removing the proteins precipitated, subjecting the obtained solution to chromatography on a gel with a void volume below a molecular weight of 4000 daltons, eluting with a solution of pH 6.0 to 7.0, concentrating the biologically active fractions, chromatographing again on a gel with a void volume below a molecular weight of 4000 daltons, fractionating by elution with water, lyophilizing the active fractions, dissolving the lyophilized fractions in a buffer of pH 8.1 to 8.2, adding trypsin and chymotrypsin to the solution in a substantially identical amount of 0.01 to 0.2 by weight as calculated for the total weight of the lyophilized product, subjecting the mixture to digestion at a temperature of 36.degree. C. to 39.degree. C., preferably with occasionally shaking from 20 to 30 hours, adding after the first 5 hours trypsin and chymotrypsin in a substantially half amount as calculated for the original enzyme quantity and continuing the digestion, then adding trichloroacetic acid to the reaction mixture up to a concentration of 4 to 6 weight/volume percent at a temperature between 0.degree. and 10.degree. C., keeping the mixture at a temperature between -15.degree. C. and 5.degree. C. for 1 to 24 hours, removing the insoluble part, subjecting the reaction mixture to chromatography on a gel with a void volume below a molecular weight of 4000 daltons, fractionating by elution with water and lyophilizing the biologically active fractions.

DETAILED DESCRIPTION What we claim is: 1.
A process for isolating a food intake suppressant from human or animal blood serum which comprises subjecting the human and/or animal blood serum to ultrafiltration on a membrane or hollow fiber ultrafilter passing a filtrate containing substances of a molecular weight of at most 50,000 daltons, partially evaporating the filtrate, removing the insoluble part from the concentrate obtained, adding trichloroacetic acid up to a concentration of 5 to 25 weight/volume percent to the liquid phase at a temperature of 0.
degree.
C.
to 10.
degree.
C.
, removing the proteins precipitated, subjecting the obtained solution to chromatography on a gel with an elution solution of pH 6.
0 to 7.
0, concentrating the biologically active fractions, chromatographing again on a gel with a void volume having a molecular weight of 3000 to 4000 daltons, fractionating by elution with water, lyophilizing the active fractions, dissolving the lyophilized fractions in a buffer of pH 8.
1 to 8.
2, adding trypsin and chymotrypsin to the solution in substantially identical amounts of 0.
01 to 0.
2 by weight as calculated for the total weight of the lyophilized product, subjecting the mixture to digestion at a temperature of 36.
degree.
C.
to 39.
degree.
C.
for 20 to 30 hours, adding after the first 5 hours an equal quantity of trypsin and chymotrypsin in a substantially half amount as calculated for the original enzyme quantity and continuing the digestion, then adding trichloroacetic acid to the reaction mixture up to a concentration of 4 to 6 weight/vol.
% at a temperature between 0.
degree.
C.
and 10.
degree.
C.
, keeping the mixture at a temperature between -15.
degree.
C.
and 5.
degree.
C.
for 1 to 24 hours, removing the insoluble part, subjecting the reaction mixture to chromatography on a gel with a void volume having a molecular weight of 3000 to 4000 daltons, fractionating by elution with water and lyophilizing the biologically active fractions to yield said food intake suppressant having a molecular weight between 40,000 and 50,000 daltons



Related patents
  Terminal methionyl bovine growth hormone and its use
According to the present invention, synthetic DNA is provided for a substantial portion of the initial coding sequence of a heterologous gene insert, and optionally, ...
  Human immune interferon
The present invention is based upon the discovery that recombinant DNA technology can be used to successfully produce human immune interferon, preferably in direct form, ...
  Method for production of an enzyme granulate
I claim: 1. In a process for production of an enzyme granulate which comprises granulating an enzyme composition comprising enzyme, filler, binder, and from 1.5-40% by ...
  Process for preparing narasin
The new microorganism of this invention is a biologically pure culture derived from a soil sample collected near the Surinam River, Surinam, South America. The culture ...
  Reversible optical waveguide vapor sensor
Accordingly, it is an object of the invention to detect small amounts of a chemical in air and in other gases. Another object is to provide a device for such purpose ...
  Biotinidase-resistant biotinylated compound and methods of use thereof
This invention relates to biotinidase-resistant biotinylated compounds containing a chemical fragment having the structure: ##STR2## wherein R.sub.1 and R.sub.3 are ...
  Method of recovering shiga-like toxins and vaccines comprising inactivated shiga-like toxin
This invention provides a facile, efficient and reproducible method for recovering biologically active Shiga-like toxins from a sample using an affinity ligand ...
  Assays for shiga toxin and shiga-like toxins
OF THE INVENTION The present invention relates to a substantially pure antigenic or peptide protein related to Shiga toxin (ST) or Shiga-like toxins I or II (SLT-II, SLT...
  Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
OF THE INVENTION Histologic examination of colonic tissue has revealed no evidence of attachment of E. coli O157:H7 to bovine colonic tissue. The rumen appears to be ...
  Feline leukemia virus vaccines
OF THE INVENTION Any immunogenic FeLV protein may be expressed in baculovirus following the methods and techniques described here. For instance, the location and ...

0.074

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved